The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

GWP GW PHARMACEUTICALS PLC ORD 0.1P




 Page 2 of 4

Previous | 1 | 2 | 3 | 4 | Next

Time/Date Code Headline Source Impact
12:00 11-May-2015 GWP Half Yearly Report RNS -0.76% Down
12:00 11-May-2015 GWP Initiates Ph3 Pivotal Study of Epidiolex in LGS RNS -0.76% Down
11:45 11-May-2015 GWP Holding(s) in Company RNS -0.76% Down
11:45 11-May-2015 GWP Holding(s) in Company RNS -0.76% Down
16:22 08-May-2015 GWP Holding(s) in Company RNS -0.20% Down
12:00 06-May-2015 GWP Notice of Results RNS +0.37% Up
12:00 06-May-2015 GWP Initiates Phase 2 Trial of CBDV in Epilepsy RNS +0.37% Up
07:01 06-May-2015 GWP Closing of U.S. Public Offering of ADSs RNS +0.37% Up
15:28 01-May-2015 GWP Holding(s) in Company RNS -4.96% Down
07:30 01-May-2015 GWP Holding(s) in Company RNS -4.96% Down
07:00 29-Apr-2015 GWP Pricing of U.S. Public Offering of ADSs RNS -7.03% Down
07:00 28-Apr-2015 GWP Proposed Public Offering of ADSs RNS -6.78% Down
12:00 27-Apr-2015 GWP US Patent Allowance for Use of Cannabidivarin RNS -3.64% Down
12:00 24-Apr-2015 GWP Orphan Drug Designation for CBD in NHIE RNS -0.36% Down
07:00 23-Apr-2015 GWP New Physician Reports of Epidiolex Treatment RNS +2.00% Up
12:00 21-Apr-2015 GWP Starts 2nd Ph 3 Epidiolex Trial in Dravet Syndrome RNS +6.06% Up
07:00 14-Apr-2015 GWP New Epidiolex Data Released by AAN RNS +16.25% Up
14:03 01-Apr-2015 GWP Holding(s) in Company RNS +3.19% Up
12:00 31-Mar-2015 GWP Starts Ph 3 Trial for Epidiolex in Dravet Syndrome RNS +3.10% Up
17:18 17-Mar-2015 GWP Holding(s) in Company RNS +9.80% Up

 Page 2 of 4

Previous | 1 | 2 | 3 | 4 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.

Market

Company Information
Updated Monthly
Company address Porton Down Science Park, Salisbury, SP4 0JQ, United Kingdom
Company website http://www.gwpharm.com
Market cap(in millions)* £ 1,427.63
Listing/Admission to trading 28 Jun 2001
Trading service SETS
Market AIM
Listing category -
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
05-Sep-15
FTSE index FTSE AIM All-Share,FTSE AIM 100,FTSE AIM UK 50,FTSE AIM All-Share - Health Care
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment AMSM
MiFID Status MTF
Exchange market size 3,000
SEDOL 3054468
ISIN number GB0030544687



GW PHARM. share - news analysis